Company: NIVFW
Filing Date: 2025-09-15
Form Type: F-1
Source: 0001213900-25-087717
Chunk: 40

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-15
Form: F-1
Chunk 40
---
 historical revenue growth should not be considered indicative of its future performance. Further, in future periods, its revenue growth could slow or decline for a number of reasons, including risks, challenges and uncertainties that NewGenIvf has encountered and may continue to encounter that are frequently experienced by companies at an early stage, slowing demand for its solutions and fertility services in general, changes in utilization trends by its clients, general economic slowdown, an increase in unemployment, an increase in competition, changes to health care trends and regulations, changes to science relating to the fertility market, a decrease in the growth of the fertility market, or its failure, for any reason, to continue to take advantage of growth opportunities. If NewGenIvf’s assumptions regarding these risks and uncertainties and its future revenue growth are incorrect or change, or if it does not address these risks successfully, its operating and financial results could differ materially from its expectations, and its business could suffer. Our planned Solana strategy may not be successful and exposes us to various risks, including risks associated with the Solana network, SOL token and the blockchain sector. On June 2, 2025, we announced plans to invest up to US$30 million in staking the digital asset SOL (the native token of the Solana network) and funding such investment using our existing credit facilities. “Staking SOL” refers to the process of delegating our acquired SOL tokens to independent validator nodes on the Solana network to participate in its proof-of-stake consensus mechanism. In return for this delegation, we earn staking rewards, which are distributed approximately every 2-3 days (each period known as an “epoch”). This strategy is intended to generate returns through (i) these staking rewards, currently yielding approximately 6.78% APY, and (ii) potential appreciation in the value of the SOL tokens we hold. Our primary costs include validator commissions (typically 0-10% of rewards), network transaction fees, custodial service fees, and, if credit facilities are used for funding, interest expense on such credit facilities. We have structured this strategy in phases:

| ● | Phase 1 (completed June-July 2025): We acquired                                                           
 an initial position of 6,703.99 SOL (approximately $1.24 million at acquisition) as an operational pilot. |

| ● | Phase 2 (Q3 2025 – Q4 2026): We plan to                                                                                                 
 systematically deploy the remaining capital (approximately $28.76 million) using